Malaysia freezes bank accounts linked to GISB after child abuse allegations
Planned merger of Super RTL, Nickelodeon withdrawn, says German cartel office
Frenchman accused of mass abuse of wife says "I am a rapist", seeks forgiveness - media
Budapest and Poland's Wroclaw reinforce their river banks ahead of more flooding in central Europe
EU chief unveils her new team after a long and bumpy road; women get top roles
Myanmar's death toll from Typhoon Yagi rises past 200, with tallying hindered by civil war
Sweden to boost defence spending by $1.3 billion in 2025
Germany's Scholz: Intel committed to German site despite delay
Indonesia parliamentary committee approves incoming govt's budget
UMG, Taylor Swift's music label, sees higher profit, helped by superfans
Japan hails record Emmy success for 'Shogun' as cultural win
(Reuters) - British drugmaker GSK said on Tuesday it had signed a $1 billion agreement with Johnson & Johnson-owned Janssen for exclusive rights to further develop and commercialize the U.S.-based company's hepatitis B therapy.
Exclusive rights to the therapy, JNJ-3989, which Arrowhead Pharmaceuticals initially developed and licensed to Janssen in 2018, will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, it said.
(Reporting by Eva Mathews in Bengaluru; Editing by Shinjini Ganguli)
